Literature DB >> 15542519

Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome.

G Kristjánsson1, P Venge, A Wanders, L Lööf, R Hällgren.   

Abstract

BACKGROUND AND AIMS: There is a clear need for a rapid, simple, safe, and sensitive method of determining the type and intensity of inflammation in the gut mucosa in clinical practice. In this study, we have evaluated the potential of a new method, the mucosal patch technique, in patients with and without apparent gut inflammation, as assessed by conventional diagnostic procedures. SUBJECTS AND METHODS: The technique tested is based on the idea that inflammatory mediators released from the rectal mucosa can be absorbed by and then extracted from cellulose patches brought into contact with the mucosa by use of an instrument with an inflatable balloon. Measurements were performed in healthy controls (n = 16) and in patients with active (n = 19) and inactive ulcerative colitis (UC, n = 8), collagen colitis (CC, n = 12), coeliac disease (n = 13), and irritable bowel syndrome (IBS, n = 13).
RESULTS: Inflammatory mediators from neutrophils (myeloperoxidase (MPO)) and eosinophils (eosinophil cationic protein (ECP)) were increased on average 300- and 10-fold, respectively, in patients with active UC compared with healthy controls and were correlated with the endoscopic score. Patients with inactive UC, CC, coeliac disease, and IBS exhibited no endoscopic signs of inflammation. These patient groups had significantly lower levels of MPO and ECP than the active UC group but showed on average a four- to sevenfold increase in MPO compared with healthy controls.
CONCLUSION: The mucosal patch technique was well tolerated by patients and easily applied by the investigator. Pronounced neutrophil and eosinophil involvement in UC was demonstrated. With the high sensitivity of the technique, low degree mucosal neutrophil activation could also be quantified in patients with CC and UC in clinical remission. The finding of increased neutrophil involvement in patients with IBS contributes to the pathophysiological ideas of this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542519      PMCID: PMC1774319          DOI: 10.1136/gut.2003.036418

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  33 in total

1.  Activation of the mucosal immune system in irritable bowel syndrome.

Authors:  Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

2.  VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS.

Authors:  J H BARON; A M CONNELL; J E LENNARD-JONES
Journal:  Br Med J       Date:  1964-01-11

3.  Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis.

Authors:  M Carlson; Y Raab; L Sevéus; S Xu; R Hällgren; P Venge
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

4.  Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis.

Authors:  P Sangfelt; M Carlson; M Thörn; L Lööf; Y Raab
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

5.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.

Authors:  R C Spiller; D Jenkins; J P Thornley; J M Hebden; T Wright; M Skinner; K R Neal
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

6.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.

Authors:  K Geboes; R Riddell; A Ost; B Jensfelt; T Persson; R Löfberg
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

7.  Evidence of local eosinophil activation and altered mucosal permeability in collagenous colitis.

Authors:  Y Taha; M Carlson; M Thorn; L Loof; Y Raab
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

8.  Increased mast cells in the irritable bowel syndrome.

Authors:  M O'Sullivan; N Clayton; N P Breslin; I Harman; C Bountra; A McLaren; C A O'Morain
Journal:  Neurogastroenterol Motil       Date:  2000-10       Impact factor: 3.598

9.  A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease.

Authors:  Christer G B Peterson; Elisabeth Eklund; Yesuf Taha; Yngve Raab; Marie Carlson
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

Review 10.  Monitoring the allergic inflammation.

Authors:  P Venge
Journal:  Allergy       Date:  2004-01       Impact factor: 13.146

View more
  34 in total

Review 1.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.

Authors:  Maria Lampinen; Amanda Waddell; Richard Ahrens; Marie Carlson; Simon P Hogan
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

3.  Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy.

Authors:  Giuseppe Leoncini; Vincenzo Villanacci; Maria Grazia Marin; Valentina Crisafulli; Moris Cadei; Elisabetta Antonelli; Claudio Leoci; Gabrio Bassotti
Journal:  Tech Coloproctol       Date:  2018-12-10       Impact factor: 3.781

Review 4.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.

Authors:  Lena Ohman; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01-26       Impact factor: 46.802

5.  High-Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease.

Authors:  Jee-Yon Lee; Stephanie A Cevallos; Mariana X Byndloss; Connor R Tiffany; Erin E Olsan; Brian P Butler; Briana M Young; Andrew W L Rogers; Henry Nguyen; Kyongchol Kim; Sang-Woon Choi; Eunsoo Bae; Je Hee Lee; Ui-Gi Min; Duk-Chul Lee; Andreas J Bäumler
Journal:  Cell Host Microbe       Date:  2020-07-14       Impact factor: 21.023

6.  Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome.

Authors:  Chang Geun Lee; Jun Kyu Lee; Yun-Seong Kang; Seungmin Shin; Jae Hak Kim; Yun Jeong Lim; Moon-Soo Koh; Jin Ho Lee; Hyoun Woo Kang
Journal:  Am J Gastroenterol       Date:  2015-01-13       Impact factor: 10.864

Review 7.  Probiotic use in irritable bowel syndrome.

Authors:  Patrick Young; Brooks D Cash
Journal:  Curr Gastroenterol Rep       Date:  2006-08

8.  Gut mucosal granulocyte activation precedes nitric oxide production: studies in coeliac patients challenged with gluten and corn.

Authors:  G Kristjánsson; M Högman; P Venge; R Hällgren
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

9.  Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase.

Authors:  B J R Whittle; C Varga; A Berko; K Horvath; A Posa; J P Riley; K A Lundeen; A M Fourie; P J Dunford
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

Review 10.  Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.

Authors:  Jan Däbritz; Jason Musci; Dirk Foell
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.